London, United Kingdom
Aureum Diagnostics Limited is a UK-based manufacturing startup founded in 2021. The company's slogan, "Aureum’s breakthrough point of care diagnostics platform to meet rapidly evolving global healthcare needs," reflects its mission to address critical global healthcare challenges. Aureum has developed a ground-breaking Point of Care diagnostics platform that offers unparalleled performance across various critical applications. The platform uses novel electrochemical technology to enable rapid, sensitive, accurate, and cost-effective measurement of metabolites, proteins, and nucleic acid targets in an easy-to-use "sample to result" format.
Over the last 5 years, Aureum has secured over £1.5 million in competitively won grants and research studentships to support its innovative work in developing novel biosensor technologies for various diseases. The company has a particular focus on addressing the challenges posed by Covid-19 and has successfully developed several novel biosensor strategies for SARS-CoV-2 through a Chief Scientist Office Scotland Covid Rapid Response Project.
The company recently received a Seed Round investment at 01 January 2023 from Norcliffe Capital Limited, signaling investor confidence in Aureum's innovative approach to point of care diagnostics. With its compelling technology and strong backing, Aureum is poised to make significant contributions to the global healthcare industry.
